Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04134494 · ClinicalTrials.gov registry record · NA

Laser Treatment for Vulvar Lichen Sclerosus

A NA study, sponsored by Beth Israel Deaconess Medical Center.

Terminated
Registry status
NA
Development phase
15
Enrollment target

NCT04134494 is a NA study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04134494, a NA study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.

TERMINATED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

The object of this non-randomized, prospective study is to assess the effectiveness of ablative fractional 2940 nm laser treatment of vulvar lichen sclerosus. Aim 1: To assess physical and histological changes related to vulvar lichen sclerosus before and after laser treatment. Aim 2: To evaluate participant satisfaction for laser treatment of vulvar lichen sclerosus. The results of this study will determine whether fractional 2940 nm laser is an effective treatment option for lichen sclerosus, particularly for those participants not eligible for high-dose topical steroids or who have failed prior treatment with topical steroids.

Interventions

  • DEVICE Ablative Fractional 2940 nm Laser

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2020-01-01
Est. Completion 2022-12-31
Phase NA

What the Registry Record Tells You About NCT04134494

The ClinicalTrials.gov registry entry for NCT04134494 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ablative Fractional 2940 nm Laser is the first listed.

NCT04134494 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04134494 about?

NCT04134494 is a clinical study titled "Laser Treatment for Vulvar Lichen Sclerosus". The object of this non-randomized, prospective study is to assess the effectiveness of ablative fractional 2940 nm laser treatment of vulvar lichen sclerosus. Aim 1: To assess physical and histological changes related to vulvar lichen sclerosus before and after laser treatment. Aim 2: To evaluate ...

What is the current status of trial NCT04134494?

This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2020-01-01. Estimated completion is 2022-12-31.

What interventions are being tested in trial NCT04134494?

The interventions under investigation include: Ablative Fractional 2940 nm Laser (DEVICE).

Who is sponsoring clinical trial NCT04134494?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.